

MICROMEDEX

CLINICAL KNOWLEDGE

BENEFITS

- Improves patient safety
- Decreases adverse events
- Saves clinicians time
- Increases pediatric medication accuracy

FEATURES

- Pediatric referential drug monographs and enteral nutrition information
- Calculators for pediatric drug dosing based on patient-specific information, including indication, weight, and age
- Comparison tables for enteral nutrition
- Evidence-based data backed by the clinical rigor of Micromedex

Ensure Medication Safety for Pediatric Patients With the Most Timely and Trusted Information Available

Micromedex® Pediatric Drug Information was developed specifically for pediatric clinicians and pharmacists who must accurately determine drug dosages and nutritional support for pediatric patients, according to evidence-based practices.

Micromedex Pediatric Drug Information provides evidence-based drug information and age- and indication-specific drug dosing calculators for the pediatric population. Our solutions help to improve safety in the care of these vulnerable patients, and our evidence-based systems provide clinicians with tools to efficiently and safely manage complex scenarios for pediatric patients.

Pediatric-Specific

Our drug dosing recommendations and calculations are based on the best available pediatric-specific evidence and greatly reduce the risk for inadvertent adverse events.

Our information includes age- and indication-specific calculators for the most accurate drug dosages.

Comprehensive Data

Micromedex Pediatric Drug Information provides unparalleled scope, breadth, and depth of information on commonly used medications, infant formulas, human milk fortifiers, and prescription enteral formulas for the pediatric population. It is backed by the editorial content and clinical rigor of Micromedex, using evidence-based data developed after careful review of thousands of medical journals and other research. Content is intended for pediatric patients ages 29 days to 18 years.

Easy, Intuitive Interface

Micromedex Pediatric Drug Information is unique in that it provides weight-based dosing, as well as age-specific algorithms for more accurate dosing.

Medication Management Pediatric Drug Information

TRUVEN FACT: Pediatric patients are approximately three times more vulnerable than adults to medication errors.

Pediatric Monograph Example

Selected Drug Information

Amphotericin B Liposome		
Dose	Administration	Uses
Monitoring	Adverse Effects	Pharmacology
Special Considerations/Preparation	Solution Compatibility	Solution In/Compatibility
Terminal Injection Site Compatibility	References	

Dose - Amphotericin B Liposome

Blastomycosis, Severe Disease: 3 to 5 mg/kg IV once daily for 1 to 2 weeks, followed by stepdown therapy with oral itraconazole 10 mg/kg/day orally (maximum 400 mg/day) in 2 divided doses for total of 12 months [1].

Cryptococcosis, including HIV-Infected Children:
Meningitis: 4 to 6 mg/kg IV once daily, in combination with flucytosine 25 mg/kg orally four times daily (preferred), followed by fluconazole 6 to 12 mg/kg orally daily for 8 weeks as consolidation therapy [2] [3].
Disseminated Disease (central nervous system (CNS) not involved) or Severe Pulmonary Disease: Primary Therapy: 3 to 5 mg/kg IV once daily with or without flucytosine [2] [3].
Localized Disease including Isolated Pulmonary Disease (CNS not involved): Alternative Therapy: 3 to 5 mg/kg IV once daily [3].

Febrile Neutropenia, Empiric Treatment: 3 mg/kg IV once daily [4] [5] [6].

Histoplasmosis, Progressive Disseminated Histoplasmosis (intolerant to conventional amphotericin B): 3 to 5 mg/kg IV once daily for 4 to 6 weeks [7].

Histoplasmosis-HIV Infection, Moderately Severe to Severe Disseminated Disease: 3 mg/kg IV once daily for 1 to 2 wk, followed by consolidation therapy with itraconazole 2 to 5 mg/kg orally (maximum 200 mg/dose) three times daily for first 3 days, followed by 2 to 5 mg/kg orally (maximum 200 mg/dose) orally twice daily for 12 months [5].

CNS Infection: 5 mg/kg IV once daily for 4 to 6 weeks, followed by consolidation therapy with itraconazole 2 to 5 mg/kg orally (maximum 200 mg/dose) three times daily for first 3 days, followed by 2 to 5 mg/kg orally (maximum 200 mg/dose) twice daily for at least 12 months [3].

Systemic Fungal Infections (Aspergillosis, Candidiasis): 3 to 5 mg/kg IV once daily [4].

Systemic Fungal Infections-HIV Infection (Aspergillosis and Invasive Candidiasis, alternative therapy): 5 mg/kg IV once daily [3].

Visceral Leishmaniasis:
Immunocompetent patients: 3 mg/kg IV once daily on days 1 to 5, and on days 14 and 21 [4].
Immunocompromised patients: 4 mg/kg IV once daily on days 1 to 5, and on days 10, 17, 24, 31, and 38 [4].

Administration - Amphotericin B Liposome

Administer by IV infusion at a concentration of 1 to 2 mg/mL over a period of approximately 60 (if well tolerated) to 120 minutes. To provide sufficient volume for infusion, a final concentration of 0.2 to 0.6 mg/mL may be appropriate for infants and small children. May increase infusion time if patient experiences intolerance during the infusion. Flush existing IV line with D₅W prior to infusion or administer in a separate IV line. In-line filter with pore diameter no less than 1 micron may be used [4].

Uses - Amphotericin B Liposome

Treatment of serious, life-threatening, systemic fungal infections including aspergillosis, blastomycosis, candidiasis, cryptococcosis, and histoplasmosis [3] [1] [6] [7]. Liposomal amphotericin B is considered an alternative to voriconazole for primary treatment of invasive aspergillosis, as well as an acceptable agent for salvage therapy [8].

Corresponding Pediatric Drug Dosing Calculator

Calculator Mode: **PEDIATRIC**

Amphotericin B Liposome

Drug Use: **Fungal infection**
 Fungal infection
 Visceral leishmaniasis

Drug Route: **IV**
 IV

5 Years, 11 Months 15 kg

Calculator Notes
 Do not flush IV line or mix AmBisome with Normal Saline - precipitation will occur.

Pediatrics	Ordered
3 to 6 mg/kg/dose	Dose <input type="text" value="3"/> mg/kg/dose
every 24 hours	Interval every <input type="text" value="24"/> hours
over 1 to 4 hours	Admin. over <input type="text" value="120"/> minutes
0.2 to 2 mg/mL	Conc. <input type="text" value="2"/> mg/mL
	Dose amount 45 mg/dose
	Dose volume 23 mL/dose
	Delivery rate 11.5 mL/hour

Change Drug **Reset Form** **Calculate** **Print** **Drug Monograph** **Comments**



The National Institute of Health and Care Excellence (NICE) has accredited the process used by Truven Health Analytics to develop content used in its Micromedex® Solutions. For full details on our accreditation visit: www.nice.org.uk/accreditation

FOR MORE INFORMATION

To learn more about Micromedex solutions, visit truvenhealth.com/global, or email us at globalhealthcare@truvenhealth.com

FORTIFIED EVIDENCE | Rated, Intelligent, Single-Sourced

- Evidence-based for over 40 years
- Objectively validated, referenced, and sourced
- Unique key-factor strength-rating system
- In-house clinician editors
- Comprehensive single source

TRUVEN
HEALTH ANALYTICS™

Truven Health Analytics delivers unbiased information, analytic tools, benchmarks, and services to the healthcare industry. Hospitals, government agencies, employers, health plans, clinicians, pharmaceutical, and medical device companies have relied on us for more than 30 years. We combine our deep clinical, financial, and healthcare management expertise with innovative technology platforms and information assets to make healthcare better by collaborating with our customers to uncover and realize opportunities for improving quality, efficiency, and outcomes. With more than 2,000 employees globally, we have major offices in Ann Arbor, Mich.; Chicago; and Denver. Advantage Suite, Micromedex, ActionOI, MarketScan, and 100 Top Hospitals are registered trademarks or trademarks of Truven Health Analytics.

truvenhealth.com | 1.800.525.9083

©2013 Truven Health Analytics Inc. All rights reserved. All other product names used herein are trademarks of their respective owners. INTL 12612 0613